In December 2023, the FDA approved two gene therapies, Lyfgenia and Casgevy, for treating sickle cell disease (SCD) in individuals aged 12 and older. Lyfgenia uses a lentiviral vector to deliver a modified beta-globin gene, while Casgevy employs CRISPR-Cas9 to enhance fetal hemoglobin production. These approvals mark significant progress in gene therapy for SCD, following decades of research and clinical trials. The therapies aim to reduce vaso-occlusive events (VOEs), a major complication of SCD. Lyfgenia's development involved multiple clinical trials, with improvements in gene therapy protocols. However, two patients developed acute myeloid leukemia, leading to warnings about hematologic malignancy risks. Casgevy, the first CRISPR-based gene therapy approved, has high fidelity but may have off-target effects, which are monitored. Both therapies are indicated for SCD patients 12 years and older with recurrent VOEs. They have shown high efficacy, with 94% of participants achieving complete resolution of VOEs. Despite FDA approval, challenges remain in defining SCD centers of excellence, ensuring access, and addressing long-term safety and cost issues. Gene therapy is transformative but not curative, requiring long-term follow-up and access to specialized care. Cost remains a barrier, with therapies priced at over $2 million. Efforts to improve access and affordability are crucial for widespread use. The FDA requires 15 years of follow-up, highlighting the need for registries to track long-term effects. The approval of these therapies represents a milestone in SCD treatment, but ongoing research is needed to enhance access, reduce adverse events, and improve patient outcomes. The contributions of patients who participated in clinical trials have been vital, paving the way for future advancements in gene therapy for SCD.In December 2023, the FDA approved two gene therapies, Lyfgenia and Casgevy, for treating sickle cell disease (SCD) in individuals aged 12 and older. Lyfgenia uses a lentiviral vector to deliver a modified beta-globin gene, while Casgevy employs CRISPR-Cas9 to enhance fetal hemoglobin production. These approvals mark significant progress in gene therapy for SCD, following decades of research and clinical trials. The therapies aim to reduce vaso-occlusive events (VOEs), a major complication of SCD. Lyfgenia's development involved multiple clinical trials, with improvements in gene therapy protocols. However, two patients developed acute myeloid leukemia, leading to warnings about hematologic malignancy risks. Casgevy, the first CRISPR-based gene therapy approved, has high fidelity but may have off-target effects, which are monitored. Both therapies are indicated for SCD patients 12 years and older with recurrent VOEs. They have shown high efficacy, with 94% of participants achieving complete resolution of VOEs. Despite FDA approval, challenges remain in defining SCD centers of excellence, ensuring access, and addressing long-term safety and cost issues. Gene therapy is transformative but not curative, requiring long-term follow-up and access to specialized care. Cost remains a barrier, with therapies priced at over $2 million. Efforts to improve access and affordability are crucial for widespread use. The FDA requires 15 years of follow-up, highlighting the need for registries to track long-term effects. The approval of these therapies represents a milestone in SCD treatment, but ongoing research is needed to enhance access, reduce adverse events, and improve patient outcomes. The contributions of patients who participated in clinical trials have been vital, paving the way for future advancements in gene therapy for SCD.